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Abstract
Purpose Dolutegravir (DTG) is primarily metabolized by
UGT1A1 with CYP3A as a minor route. Carbamazepine
(CBZ) is a potent inducer of these enzymes; thus, the effect
of oral extended-release CBZ on DTG pharmacokinetics (PK)
was evaluated to provide dose recommendation when co-
administered.
Methods This was a single-center, open-label, fixed-se-
quence, crossover study in healthy adults. Subjects received
three treatments: DTG 50 mg every 24 h (q24h) × 5 days in
per iod 1, fol lowed by CBZ 100 mg every 12 h
(q12h) × 3 days, then 200 mg q12h × 3 days, then 300 mg
q12h × 10 days in period 2, and DTG 50 mg q24h + CBZ
300 mg q12h × 5 days in period 3. No washout intervals
occurred. Each dose was administered with a moderate-fat
meal. Serial PK samples for DTG were collected on day 5 of
periods 1 and 3. Plasma DTG PK parameters were determined
with non-compartmental analysis. Geometric least-squares
mean ratios (GMRs) and 90% confidence intervals (CIs) were
generated by the mixed-effect model for within-subject treat-
ment comparisons. Safety assessments were performed
throughout the study.
Results Sixteen subjects enrolled; 14 completed the study.
CBZ significantly reduced DTG exposure: GMRs (90 % CI)
for DTG + CBZ versus DTG alone were 0.51 (0.48–0.549),
0.67 (0.61–0.73), and 0.27 (0.24–0.31) for area under the
curve from time zero to the end of the dosing interval
(AUC(0-τ)), maximum observed plasma concentration
(Cmax), and plasma concentration at the end of the dosing
interval (Cτ), respectively. DTG alone and co-administered
with CBZ was well tolerated.
Conclusion Integrase strand transfer inhibitor-naive subjects
taking CBZ should receive DTG 50 mg twice daily versus
once daily, as is recommended with other potent UGT1A/
CYP3A inducers.
ClinicalTrials.gov: NCT01967771
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Introduction
Dolutegravir (DTG, Tivicay®, ViiV Healthcare) is an HIV
integrase strand transfer inhibitor approved for use in combi-
nation with other antiretrovirals for the treatment of HIV in-
fection in adults and adolescents. The usual dose in integrase
strand transfer inhibitor-naive subjects is 50mg once daily [1].
Dolutegravir is a substrate of P-glycoprotein (P-gp) and is
primarily metabolized by uridine diphosphate glucuronosyl-
transferase (UGT) 1A1 with a minor component (approxi-
mately 10 %) via cytochrome P450 (CYP) 3A4 [1, 2].
Clinically significant drug interactions requiring a dose adjust-
ment with DTG have not been observed with inhibitors of
UGT1A1, CYP3A4, or P-gp [3, 4]. However, a clinically
significant decrease in exposure has been observed with
DTG when co-administered with the strong CYP3A4 in-
ducers that include tipranavir/ritonavir, efavirenz, and rifam-
pin [5, 6]. These enzyme inducers require the dose of DTG to
be increased from 50 mg once daily to 50 mg twice daily.
Neurologic manifestations of HIV infection are quite
diverse, and many individuals with HIV infection who are
taking antiretroviral therapy require treatment with
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anticonvulsants. Anticonvulsant medications are commonly
used in patients with HIV either for seizure management or
for expanded indications such as neuropathic pain and
psychiatric disorders, including depression [7, 8].
Carbamazepine (CBZ) is an antiepileptic drug (AED) that
has been used for the treatment of depression as well as
trigeminal neuralgia. Carbamazepine is a potent enzyme
inducer and is known to induce its own metabolism,
resulting in a shorter half-life (12–17 h) and lower exposure
following chronic dosing compared with the half-life
(25–65 h) and exposure following single dosing [11]. In
addition, potent induction of CYP3A4 and UGT1A1
enzymes by CBZ can lead to underexposure of drugs that
are metabolized by these enzymes [9, 10]. Considering the
metabolic pathways of DTG and CBZ and that CBZ may be
prescribed to HIV-infected subjects, an evaluation of the ef-
fects of CBZ on DTG pharmacokinetics (PK) was warranted.
In vitro, DTG demonstrated minimal or no direct inhibition
of CYP isozymes, UGT1A1, UGT2B7, andmany transporters
(P-gp, breast cancer resistance protein, OATP1B1, OATP1B3,
MRP2) and was not an inducer of CYP1A2, CYP2B6, or
CYP3A4 [1, 2]. Dolutegravir also had no significant effect
on midazolam exposure, a probe substrate for CYP3A4, in
healthy subjects [1]. Carbamazepine is primarily metabolized
in the liver by CYP3A. However, based on DTG enzyme
interaction profile, it was not expected to affect CBZ PK; thus,
the primary objective of this study was to evaluate the effect of
CBZ on DTG PK in healthy subjects and not vice versa.
Methods
Study design
This was a phase I, single-site, open-label, fixed-sequence,
crossover study with three treatment periods to evaluate the
effect of an oral extended-release formulation of CBZ on the
steady-state PK of orally administered DTG in 16 healthy
subjects. The study was conducted in accordance with the
principles of the Declaration of Helsinki. A written informed
consent was obtained from all subjects, and the protocol was
approved by the institutional review board of the study site.
The trial was registered at ClinicalTrials.gov (NCT01967771;
protocol number: 200901).
Each subject was evaluated with physical examination,
medical history, and laboratory testing at a screening visit
conducted within 30 days prior to the first dose of drug and
at a follow-up visit 7 to 14 days after the last dose of study
drug. Eligible subjects were 18 to 65 years of age, had a
minimum weight requirement of 45 kg for women and
50 kg for men, and a bodymass index requirement of between
18.5 and 31.0 kg/m2. Subjects with positive pre-study
drug/alcohol screens, positive HIV antibody test results, and
positive serum or urine human chorionic gonadotropin test
results for pregnancy, as well as Asians with positive HLA-
B*1502 allele (carriage is associated with a risk of hypersen-
sitivity reactions with exposure to CBZ) and subjects with
allergies to tricyclic antidepressants, were excluded. Women
of child-bearing potential agreed to protocol-specified
methods of contraception to avoid pregnancy. Subjects were
not allowed to receive prescription or non-prescription/herbal
medications within 7 days of dosing or throughout the study.
Use of antacids, vitamins, or calcium or iron supplements,
which are known to reduce DTG absorption, was strictly
prohibited within 24 h before the first dose of study medica-
tion and throughout the trial, including follow-up.
Acetaminophen was permitted with a dose that did not exceed
2 g per day.
During period 1, subjects received DTG 50 mg once daily
as a single agent for days 1 to 5. During period 2, subjects
received CBZ alone and the dose was escalated: 100 mg twice
daily for days 1 to 3, 200 mg twice daily for days 4 to 6, and
300 mg twice daily for days 7 to 16. During period 3, DTG
50 mg once daily was co-administered with CBZ 300 mg
twice daily for days 1 to 5. There was no washout between
treatment periods. As CBZ is recommended to be given with
food per product information [11], all doses in the testing unit,
including those on PK collection days, were administered
orally in the morning 30 min after the start of the moderate-
fat meal, and subjects were asked to do the same when dosing
outside the unit. Subjects were housed at the clinical research
unit from period 1, day 1, until the morning of period 2, day 8,
as well as from period 2, day 16, through period 3, day 6.
Phone call reminders and pill counts were employed when
subjects self-administered CBZ as outpatients during period
2, days 8 to 16. Serial blood samples for determining the
plasma concentration of DTG were collected on day 5 of
period 1 and day 16 of period 3 at the following times: pre-
dose (within 15 min before study dose), 0.5, 1, 2, 3, 4, 6, 12,
and 24 h after DTG dosing.
The DTG dose selected for this study was the 50 mg once-
daily dose regimen recommended for the treatment of HIV
integrase inhibitor (INI)-naive subjects. A higher dose of
50 mg twice daily is recommended for subjects with INI re-
sistance; however, this population represents a small portion
of HIV-infected subjects to be treated with DTG. Therefore,
the more common once-daily dose was evaluated in this study.
Carbamazepine dose selection was based on the range of like-
ly CBZ clinical doses [11], the time course and magnitude of
CBZ induction effect observed in other studies [10, 12], and
consideration of the risks/benefits of CBZ administration to
healthy subjects [11]. Review of prior CBZ drug-interaction
studies found most CYP3A/UGT1A1 substrate drugs demon-
strated substantially altered PKwhenCBZwas dosed between
200 and 600 mg daily for 3 weeks or less. Carbamazepine is
titrated to achieve seizure or pain control, with clinically
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effective (adult) doses ranging from 400 mg up to a maximum
of 1000 mg daily. There is no benefit, and only theoretical
risk, to dosing volunteers with a central nervous system-
active drug such as CBZ. For this reason, in this study, CBZ
was titrated upward over a 7-day period to a mid-range value
of 600 mg daily, for a total of 21 days of CBZ exposure, to
allow for complete or near complete induction. The drug-
interaction PK assessment was obtained on the last day of
period 3 (day 21).
Safety evaluations
Safety evaluations included the monitoring of adverse events
(AEs), physical examinations, clinical chemistry laboratory
tests, vital signs, and electrocardiograms. Additionally, assess-
ment of Columbia suicide severity rating scale scores was
performed throughout the study, because CBZ exposure
(along with exposure to several other AEDs) has been associ-
ated with increased risk of suicidal ideation and depression.
Bioanalytical methods
Plasma samples were analyzed for DTG by PPD, Inc.
(Middleton, WI) using a validated analytical method based
on protein precipitation with acetonitrile containing the stable
isotope-labeled internal standard (GSK1349572-d7-
15N),
followed by high-performance liquid chromatography/
tandem mass spectrometry analysis. The lower limit of quan-
tification for DTG in plasma was 20 ng/mL, and the upper
limit of quantification was 20,000 ng/mL. Precision and accu-
racy were evaluated by replicate analyses of human plasma
quality control samples prepared at five concentrations: 60,
160, 640, 2400, and 15,200 ng/mL. Precision, measured as
the percent coefficient of variation, ranged from 3.0 to 5.9 %
across the quality control range. Accuracy, expressed as the
percent difference from the mean value, ranged from −2.2 to
1.8 %. Both were within acceptance standards of 15 %.
Pharmacokinetic analysis
A non-compartmental PK analysis of the DTG concentration-
time data was conducted by Phast Clinical Data, Inc. (Raleigh,
NC). Pharmacokinet ic ana lyses of plasma DTG
concentration-time data were analyzed using Model 200 (for
extravascular administration) of Phoenix WinNonlin version
6.3 (Pharsight Corporation, St. Louis, MO). Plasma PK pa-
rameters for DTG were calculated using actual elapsed times
from dosing. The individual PK parameters that were deter-
mined included area under the curve from time zero to the end
of the dosing interval (AUC(0-τ)), maximum observed plas-
ma concentration (Cmax), plasma concentration at the end of
the dosing interval (Cτ), oral clearance, and terminal half-life.
Statistical analysis
This study was designed to estimate the magnitude of drug-
interaction effect of CBZ on the PK parameters of DTG. No
formal hypothesis was tested. Instead, an estimation approach
was used to evaluate the effect of CBZ on DTG PK.
Pharmacokinetic parameters were log-transformed and ana-
lyzed by analysis of variance to determine the point estimate
and associated 90 % confidence intervals for the difference
between test treatment (DTG + CBZ) and reference treatment
(DTG alone). These values were then back-transformed to
calculate the point and interval estimates for test-to-reference
treatment ratios on the original scale. Geometric least-squares
mean ratios and 90 % confidence intervals were generated by




Sixteen subjects, 2 females and 14 males, were enrolled and
included in the safety and PK populations. Two subjects were
prematurely discontinued from the study: one male subject
withdrew due to pyrexia/febrile illness on period 2, day 3
(CBZ alone), and one female subject withdrew due to drug-
induced hypersensitivity syndrome, increased alanine amino-
t ransferase (ALT) level , thrombocytopenia, and
maculopapular rash in period 2, day 11 (CBZ alone). The
mean (standard deviation (SD)) age was 38.6 (12.8) years
and ranged between 18 and 65 years. The mean (SD) body
mass index was 26.1 (3.2) kg/m2, height was 177.8 (6.3) cm,
and weight was 82.4 (11.5) kg. Fifteen subjects (94 %) were
not Hispanic or Latino. Six subjects (38 %) were African
American or of African heritage, while 10 subjects (63 %)
were White/Caucasian or of European heritage.
Safety
No subjects experienced AEs during period 1 (DTG alone).
Seven subjects experienced at least one AE: six subjects while
taking CBZ alone and one subject in the DTG + CBZ group
(Table 1). One subject in the DTG + CBZ group experienced a
photosensitivity event to overhead fluorescent light that oc-
curred during period 3 and resolved without interruption of
drug administration within 5 days. Headache, thrombocytope-
nia, and nausea were the only AEs that occurred in more than
one subject. No grade 3 or grade 4 AEs, deaths, or non-fatal
serious AEs were reported. Two subjects were permanently
discontinued because of AEs in period 2 (CBZ alone). One
male subject developed a febrile illness after receiving CBZ in
period 2. His lymphocyte count dropped to 0.5 × 10−3 cells/
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mm3, and ALT increased to 66 IU/L (grade 1), which was
thought to be an unrelated viral infection. The second subject
was a 23-year-old Caucasian female who developed a
suspected moderate (grade 2) hypersensitivity syndrome that
manifested with a facial rash and headache while she was
receiving 300 mg CBZ twice daily during period 2.
Laboratory analysis revealed a decrease in white blood cell
count to 3800 cells/mm3 (compared with 8800 cells/mm3 at
baseline), a decrease in platelet count to a low of 78,000 cells/
mm3 (from 159,000 3 days before), and an increase in ALT
level to a high of 151 IU/L (grade 2), while bilirubin levels
remained within normal limits. This was considered possibly
related to CBZ. The rash slowly resolved over the next
2 weeks, and all laboratory abnormalities in this subject re-
solved within 3 to 4 weeks of CBZ discontinuation.
Pharmacokinetics
Pharmacokinetic parameters following repeat-dose adminis-
tration of DTG with and without CBZ and treatment compar-
isons are shown in Table 2, and the mean (SD) concentration-
time profiles are shown in Fig. 1. The geometric mean
Table 1 Summary of drug-
related adverse events by
treatment
DTG alone (n = 16)
n (%)
CBZ alone (n = 16)
n (%)
DTG + CBZ (n = 14)
n (%)
Any event 0 6 (38) 1 (7)
Asthenia 0 1 (6) 0
Fatigue 0 0 1 (7)
Pyrexia 0 1 (6) 0
Thirst 0 1 (6) 0
Headache 0 2 (13) 0
Cognitive disorder 0 1 (6) 0
Thrombocytopenia 0 2 (13) 0
Leukopenia 0 1 (6) 0
Lymphopenia 0 1 (6) 0
Drug reaction with eosinophilia
and systemic symptoms
0 1 (6) 0
Photosensitivity reaction 0 0 1 (7)
Rash maculopapular 0 1 (6) 0
Nausea 0 1 (6) 0
ALT increased 0 1 (6) 0
Hyponatremia 0 1 (6) 0
Pain in extremity 0 1 (6) 0
Treatments: DTG alone = DTG 50mg once daily (period 1, days 1–5); CBZ = CBZ 100 mg twice daily (period 2,
days 1–3) + CBZ 200 mg twice daily (period 2, days 4–6) + CBZ 300 mg twice daily (period 2, days 7–16);
DTG + CBZ = DTG 50 mg once daily + CBZ 300 mg twice daily (period 3, days 1–5)
ALT alanine aminotransferase, CBZ carbamazepine, DTG dolutegravir
Table 2 Summary and statistical
comparison of plasma DTG PK
parameters following DTG 50mg
once-daily dose administration
with and without CBZ
PK parameter Geometric mean (CV%) Ratio of GLS means (90 % CI)
DTG alone (n = 16) DTG + CBZ (n = 14) DTG + CBZ vs DTG alone
AUC(0-τ) (μg·h/mL) 53.8 (21.4) 27.4 (22.1) 0.512 (0.477, 0.549)
Cmax (μg/mL) 4.16 (14.4) 2.77 (25.0) 0.666 (0.610, 0.726)
Cτ (μg/mL) 1.20 (39.1) 0.325 (45.9) 0.274 (0.240, 0.313)
CL/F (L/h) 0.929 (21.4) 1.83 (22.1) 1.95 (1.82, 2.10)
t1/2 (h) 12.9 (23.8) 7.31 (16.9) 0.567 (0.526, 0.611)
Treatments: DTG alone = DTG 50 mg once daily; DTG + CBZ = DTG 50 mg once daily + CBZ 300 mg twice
daily
AUC(0-τ) area under the curve from time zero to the end of the dosing interval, Cτ concentration at the end of the
dosing interval, CBZ carbamazepine, CI confidence interval, CL/F oral clearance, Cmax maximum observed
plasma concentration, CV% coefficient of variation, DTG dolutegravir, GLS geometric least squares, PK phar-
macokinetic, t1/2 terminal elimination half-life
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AUC(0-τ), Cmax, and Cτ of DTG were reduced by 49, 33,
and 73 %, respectively, when DTG was co-administered with
CBZ. Dolutegravir clearance was increased by 95 %, and its
half-life shortened from 12.9 to 7.31 h when it was co-
administered with CBZ. On an individual subject basis, the
reduction in AUC(0-τ) ranged from 27 to 58 %, and the re-
duction in Cτ ranged from 53 to 82 % for the 14 subjects with
PK results during both treatment periods.
Discussion
Carbamazepine is a potent inducer of CYP3A4 and
UGT1A1 enzymes and has been shown to decrease plas-
ma concentrations of a number of drugs [9–13]. This
study demonstrated that repeated dosing of CBZ for
21 days resulted in significant reductions of 49, 33, and
73 % in AUC(0-τ), Cmax, and Cτ, respectively, of DTG.
Dolutegravir is primarily metabolized to an inactive ether
glucuronide by UGT1A1, with some minor oxidative me-
tabolism by CYP3A4; therefore, the increased DTG clear-
ance observed in this study is likely a result of concurrent
UGT1A1 and CYP3A4 induction by CBZ. Although reg-
ulatory guidance generally recommends that the highest
possible clinical dose be used in the evaluation of a drug
as a perpetrator of drug interactions, a lower but more
commonly administered mid-range CBZ dose regimen (ti-
tration up to 600 mg/day) was selected for this study to
minimize adverse effects in the healthy subject popula-
tion. Based on the results of prior studies at the 600 mg/
day or lower doses [10, 12], the magnitude of induction
observed in this study was likely near maximal or
maximal and provided ample data for dose adjustment
decisions.
The degree of induction observed in this study of CBZ and
DTG was similar to that reported when DTG was co-
administered with other potent CYP450 enzyme inducers
such as tipranavir/ritonavir, efavirenz, and rifampin, which
reduced DTG AUC(0-τ) in the range of 36 to 49 % and Cτ
by 72 to 76% [5, 6]. The substantial reduction in Cτ observed
in these prior studies was considered clinically significant
based on the DTG exposure–antiviral response relationship
and observation that subjects receiving inducers in a phase
III trial had lower antiviral response rates [14]. Therefore,
the initial product labeling recommended an upward dose ad-
justment from 50 mg once daily to 50 mg twice daily when
DTG is being co-administered with tipranavir/ritonavir,
efavirenz, and rifampin in INI-naive subjects [1]. The present
study showed that another strong enzyme inducer, CBZ, de-
creased DTG Cτ to a similar degree (~73 %) as tipranavir/
ritonavir, efavirenz, and rifampin. Therefore, the same dose
adjustment recommendation for DTG should be applied to
CBZ. As with efavirenz and tipranavir/ritonavir, it is expected
that DTG 50 mg twice daily co-administered with CBZ will
demonstrate similar, if not higher, virologic response as that
observed in subjects receiving DTG 50mg once daily without
these inducers. In INI-resistant subjects, where the exposures
of the higher 50 mg twice-daily regimen are required for an-
tiviral activity against resistant virus, co-administration with
these strong enzyme inducers should be avoided [1].
Antiepileptic drugs are a diverse group of pharmacological
agents and can generally be classified into two groups based
on enzyme induction potential: enzyme-inducing and non-
inducing AEDs [12]. Although unstudied, the enzyme-
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Fig. 1 Mean ± SD concentration-
time profile for dolutegravir
(DTG) with and without
concomitant administration of
carbamazepine (CBZ). Treatment:
DTG alone = DTG 50 mg once
daily; DTG + CBZ = DTG 50 mg
once daily + CBZ 300 mg twice
daily
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phenobarbital are also expected to decrease DTG exposures
and require DTG dose adjustment to 50mg twice daily. Use of
non-inducing AEDs such as gabapentin, lamotrigine, leveti-
racetam, tiagabine, and topiramate may be considered as an
alternative to inducing drugs like CBZ to avoid DTG dose
adjustment.
Conclusion
This study evaluated the magnitude of a drug–drug interaction
between CBZ, a known inducer of UGT1A1 and CYP3A, and
DTG, a known substrate of UGT1A1 and CYP3A. As expect-
ed, co-administration of DTG and CBZ in healthy subjects
resulted in a potentially clinically significant decrease in
DTG AUC(0-τ), Cmax, and Cτ compared with DTG admin-
istered alone. Based on accumulated PK–pharmacodynamic
relationship data regarding DTG and the currently approved
dosing recommendation with other strong inducers, DTG
dose adjustment to 50 mg twice daily is recommended when
DTG is co-administered with CBZ.
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